Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Codexis (NASDAQ: CDXS) announced on March 4, 2026 an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support a partner's preclinical cardiovascular program.

Rhea-AI Summary

Codexis (NASDAQ: CDXS) announced on March 4, 2026 an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support a partner's preclinical cardiovascular program.

The engagement is presented as a demonstration of the platform's ability to produce material beyond early research volumes and as a potential pathway to further scale-up and commercial manufacturing, subject to program advancement.

Positive

• Manufacture of 50 g siRNA demonstrates scale beyond research volumes
• Uses proprietary ECO Synthesis platform, highlighting technical capability
• Supports preclinical cardiovascular program, enabling near-term development supply

Negative

• No financial or pricing terms disclosed, limiting revenue visibility
• Supply dependent on partner program advancement, creating timing uncertainty
• Manufacturing is for preclinical supply only, not a commercial contract

Argus Mar 4 session

+10.20% close to close Open Argus

Details

News Market Reaction – CDXS

In the Mar 4 session, CDXS gained 10.20%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with C...

Analysis

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with Codexis’s ongoing push to commercialize ECO Synthesis® for larger-scale RNA applications. The new agreement to manufacture 50 grams of siRNA adds to prior ECO Synthesis partnerships and facility build-out, reinforcing a trajectory toward higher-volume work. However, past ECO Synthesis collaborations have not always driven sustained gains, and recent insider Form 4 filings showing net selling could temper enthusiasm if momentum fades.

Key Figures

siRNA quantity: 50 grams

siRNA quantity

50 grams

Manufacturing agreement volume for preclinical program

Historical Context

5 past events · Latest: Feb 25

5 events

1. Feb 25

   Earnings date set

   24h Move

   +1.4%

   Announced date and call details for Q4 and FY2025 results.

2. Feb 17

   Conference participation

   24h Move

   +0.8%

   Noted participation and fireside chat at TD Cowen health care conference.

3. Feb 10

   Quality certification

   24h Move

   -3.1%

   Earned ISO 9001:2015 certification covering key ECO Synthesis facilities.

4. Jan 07

   Platform evaluation deal

   24h Move

   -1.2%

   Axolabs signed evaluation agreement for ECO Synthesis enzymatic RNA platform.

5. Nov 10

   GMP facility lease

   24h Move

   +3.5%

   Leased 34,000 sq ft GMP facility to expand ECO Synthesis manufacturing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

siRNA, small interfering RNA, preclinical, RNA therapeutics, +1 more

5 terms

siRNA medical

"to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

small interfering RNA medical

"to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary"

Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.

preclinical medical

"to support preclinical development of a therapeutic candidate targeting a"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

RNA therapeutics medical

"As RNA therapeutics move beyond rare diseases into larger therapeutic"

RNA therapeutics are medicines that use snippets of genetic instructions called RNA to change what proteins cells make, either by turning off harmful proteins, restoring missing ones, or teaching cells to make new proteins. Investors care because these treatments can target diseases that were hard to treat before, offering potential for big revenues but also carrying development, manufacturing and regulatory risk similar to a software update that promises major new features but may take time and testing to work reliably.

oligonucleotide therapeutics medical

"evaluation agreement with Axolabs for Oligonucleotide Therapeutics"

Short, synthetic pieces of genetic material designed to change how a cell reads or uses a specific gene, like leaving a precise instruction note that tells a cell to make less, more, or a different form of a protein. Investors care because these therapies can target diseases other drugs cannot, offering high reward if successful, but they also carry significant development, regulatory and manufacturing risks that can make outcomes binary — either strong commercial value or failure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to deliver meaningful quantities of RNA material beyond early research volumes and establishes a potential pathway to further scale-up and manufacturing, subject to program advancement.

ECO Synthesis is Codexis' proprietary technology is designed to enable efficient, scalable and high-fidelity production of complex siRNA therapeutics. As RNA therapeutics move beyond rare diseases into larger therapeutic indications, manufacturing demands increase significantly. Codexis believes its ECO Synthesis platform will address these evolving requirements by enabling efficient scale-up while maintaining product consistency.

 "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," said Alison Moore, President and Chief Executive Officer of Codexis. "Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications."

About Codexis, Inc.

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve real-world challenges associated with nucleic acid synthesis and small molecule pharmaceuticals manufacturing. The Company is currently employing its proprietary ECO Synthesis Manufacturing Platform to enable scaled manufacturing of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit codexis.com.

View original content:https://www.prnewswire.com/news-releases/codexis-signs-agreement-to-manufacture-50-g-sirna-using-its-eco-synthesis-manufacturing-platform-302704056.html

SOURCE Codexis

FAQ

What did Codexis (CDXS) announce on March 4, 2026 about siRNA manufacturing?

Codexis announced an agreement to produce 50 grams of siRNA to support preclinical work. According to the company, the batch uses the ECO Synthesis platform to demonstrate scalability beyond research volumes for a cardiovascular candidate.

How does the 50 g siRNA order affect Codexis' manufacturing capabilities (CDXS)?

It shows capacity to deliver material beyond early research amounts, indicating scale potential. According to Codexis, ECO Synthesis enables efficient, high-fidelity production aimed at larger therapeutic indications as demand grows.

Is the Codexis siRNA agreement (CDXS) a commercial-scale contract?

No, the agreement covers preclinical supply of 50 g, not commercial manufacturing. According to the company, any scale-up to commercial volumes is contingent on program advancement and future agreements.

What therapeutic area does the siRNA produced by Codexis (CDXS) target?

The material supports a preclinical therapeutic candidate targeting a cardiovascular indication. According to Codexis, this engagement demonstrates the platform's relevance as RNA therapeutics expand into larger indications.

Did Codexis (CDXS) disclose financial terms or revenue expectations for the siRNA agreement?

No, Codexis did not disclose pricing, revenue, or financial terms for the manufacturing agreement. According to the company, the announcement focuses on technical capability and potential pathway to scale-up rather than contract value.